This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
API - Meloxicam, Nystatin, Retinoic Acid, Omeprazole, Liothyronine Sodium, Levothyroxine Sodium (2015-02-13)
- Starting date:
- February 13, 2015
- Posting date:
- February 25, 2015
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type II
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-43827
Recalled Products
API - Meloxicam, Nystatin, Retinoic Acid, Omeprazole, Liothyronine Sodium, Levothyroxine Sodium
Reason
Lack of evidence of temperature control for cold storage
Depth of distribution
Wholesalers and compounding pharmacies
Affected products
API - Meloxicam, Nystatin, Retinoic Acid, Omeprazole, Liothyronine Sodium, Levothyroxine Sodium
DIN, NPN, DIN-HIM
N/ADosage form
Powder
Strength
N/A
Lot or serial number
All lots
Companies
- Recalling Firm
-
Xenex Laboratories Inc
2402 Canoe Ave,
Coquitlam
V3K 6C2
British Columbia
CANADA
- Marketing Authorization Holder
- Not Applicable